Result of AGM

Cambridge Cognition Holdings PLC

21 May 2026

 

21 May 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

Result of AGM

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.

Proxy votes were received in respect of 59.3% of the Company's issued share capital. The votes cast were as follows:

	Resolution	Votes For	Percent of votes cast For	Votes Against	Percent of votes cast Against	Votes Withheld
1	To approve the 2025 Report and Accounts	27,607,286	100%	-	-	22,265
2	To approve the 2025 Directors' Remuneration Report1	27,576,829	99.83%	47,714	0.17%	5,008
3	To appoint the auditors	27,595,679	99.92%	22,660	0.08%	11,212
4	To authorise the Directors to set the auditors' remuneration	27,602,281	99.99%	2	0.01%	27,268
5	To re-elect Stuart Gall as a Director	27,602,093	99.92%	22,440	0.08%	5,018
6	To re-elect Jon Kempster as a Director	27,601,693	99.92%	22,840	0.08%	5,018
7	To re-elect Nick Rodgers as a Director	27,601,693	99.92%	22,840	0.08%	5,018
8	To elect Rob Baker as a Director	27,602,273	99.92%	22,260	0.08%	5,018
9	To elect Ronald Openshaw as a Director	27,602,273	99.92%	22,260	0.08%	5,018
10	Authority to allot shares	27,572,233	99.79%	57,313	0.21%	5
11	Authority to disapply pre-emption rights2	27,569,635	99.80%	54,898	0.20%	5,018
12	Authority to purchase own shares on the market2	24,196,722	99.90%	25,412	0.10%	3,407,417

Notes

1. Indicates an advisory vote.

2. Indicates a Special Resolution requiring 75% of votes cast to be carried.

Enquiries:

Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer	Tel: [phone] [e-mail]
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks	Tel: [phone] Corporate Finance Corporate Broking LS Specialist Sales
Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram	Tel: [phone]

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com.

 

END